Home › NDC Lookup › RxCUI directory › RxCUI 314078

Loxapine 10 MG Oral Capsule — RxCUI 314078

RxNorm drug concept · Semantic clinical drug
RxCUI 314078 Semantic clinical drug · SCD ● Current RxNorm concept 15 FDA products 19 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI314078
Official nameLoxapine 10 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asloxapine 10 MG (as loxapine succinate 13.6 MG) Oral Capsule; loxapine succinate 10 MG Oral Capsule
FDA products mapped15
Package NDCs mapped19
Reported Medicaid activity (SDUD)31,747 prescriptions · 44 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Loxapine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Loxapine capsules treat schizophrenia. A separate inhaled product, Adasuve, calms sudden agitation linked to schizophrenia or bipolar I disorder in adults. A healthcare professiona...
  • They are taken by mouth, usually split into two to four doses a day. Your prescriber sets and adjusts the amount based on your symptoms. Take them exactly as directed and do not ch...
  • Sleepiness, dizziness and lightheadedness are common. Movement effects like tremor, stiffness or restlessness can happen. With Adasuve, an unusual taste and throat irritation are c...
  • Seek help for wheezing, shortness of breath or chest tightness after Adasuve. Also get help for high fever with severe stiffness and confusion, seizures, fainting, neck or throat m...
📖 Read our full Loxapine guide →

🕸️ Concept Web — How Loxapine 10 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Loxapine 10 MG Oral Capsule RxCUI 314078

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Loxapine 6475
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Loxapine Oral Capsule 372655
    • Loxapine Oral Product 1165350
    • Loxapine Pill 1165351
    • Oral Capsule 316965
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Loxapine 10 MG 329942

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Loxapine 10 MG SCDC · 329942
  • Loxapine Oral Capsule SCDF · 372655
  • Loxapine Oral Product SCDG · 1165350
  • Loxapine Pill SCDG · 1165351

📦 FDA Products & Package NDCs

15 products · 19 package NDCs
19 package NDCs map to RxCUI 314078 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00527-1394-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0527-1394-01) Loxapine Lannett Company, Inc. 2011-09-26
00527-1394-10 1000 CAPSULE in 1 BOTTLE, PLASTIC (0527-1394-10) Loxapine Lannett Company, Inc. 2011-09-26
00527-1395-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0527-1395-01) Loxapine Lannett Company, Inc. 2011-09-26
00527-1395-10 1000 CAPSULE in 1 BOTTLE, PLASTIC (0527-1395-10) Loxapine Lannett Company, Inc. 2011-09-26
00527-1396-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0527-1396-01) Loxapine Lannett Company, Inc. 2011-09-26
00527-1396-10 1000 CAPSULE in 1 BOTTLE, PLASTIC (0527-1396-10) Loxapine Lannett Company, Inc. 2011-09-26
00527-1397-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0527-1397-01) Loxapine Lannett Company, Inc. 2011-09-26
00527-1397-10 1000 CAPSULE in 1 BOTTLE, PLASTIC (0527-1397-10) Loxapine Lannett Company, Inc. 2011-09-26
00591-0369-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0591-0369-01) Loxapine Actavis Pharma, Inc. 1988-06-15
00591-0370-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0591-0370-01) Loxapine Actavis Pharma, Inc. 1988-06-15
00591-0371-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0591-0371-01) Loxapine Actavis Pharma, Inc. 1988-06-15
00591-0372-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0591-0372-01) Loxapine Actavis Pharma, Inc. 1988-06-15
62135-0492-60 60 CAPSULE in 1 BOTTLE (62135-492-60) Loxapine Chartwell RX, LLC 2023-03-01
62135-0493-60 60 CAPSULE in 1 BOTTLE (62135-493-60) Loxapine Chartwell RX, LLC 2023-03-01
64850-0890-01 100 CAPSULE in 1 BOTTLE (64850-890-01) Loxapine Elite Laboratories, Inc. 2020-01-27
64850-0891-01 100 CAPSULE in 1 BOTTLE (64850-891-01) Loxapine Elite Laboratories, Inc. 2020-01-27
64850-0892-01 100 CAPSULE in 1 BOTTLE (64850-892-01) Loxapine Elite Laboratories, Inc. 2020-01-27
64850-0893-01 100 CAPSULE in 1 BOTTLE (64850-893-01) Loxapine Elite Laboratories, Inc. 2020-01-27
67046-1485-03 30 CAPSULE in 1 BLISTER PACK (67046-1485-3) Loxapine Coupler LLC 2025-01-29
Observed labelers: Lannett Company, Inc. (8) · Actavis Pharma, Inc. (4) · Elite Laboratories, Inc. (4) · Chartwell RX, LLC (2) · Coupler LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.